Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

44.54USD
17 Nov 2017
Change (% chg)

$-0.11 (-0.25%)
Prev Close
$44.65
Open
$44.56
Day's High
$44.72
Day's Low
$44.40
Volume
661,417
Avg. Vol
1,221,872
52-wk High
$50.65
52-wk Low
$38.45

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $112,361.70
Shares Outstanding(Mil.): 2,526.27
Dividend: 1.64
Yield (%): 3.68

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

Fed Circuit blocks generic versions of Sanofi atrial fibrillation drug

A U.S. appeals court has blocked Teva Pharmaceutical Industries Ltd and Novartis AG's Sandoz unit from launching generic versions of Sanofi SA's atrial fibrillation drug Multaq, finding they would infringe two of Sanofi's patents.

Nov 10 2017

Sanofi strikes licence deal with Principia Biopharma on multiple sclerosis

PARIS, Nov 9 Sanofi will develop and sell an oral treatment candidate for multiple sclerosis owned by U.S firm Principia Biopharma in a licensing agreement that could total $765 million, the French drugmaker said on Thursday.

Nov 09 2017

Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales

Regeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for flagship eye treatment Eylea and its new eczema drug Dupixent, boosting its shares almost 7 percent.

Nov 08 2017

UPDATE 3-Regeneron Q3 profit easily tops Street view on Eylea, Dupixent sales

Nov 8 Regeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for flagship eye treatment Eylea and its new eczema drug Dupixent, boosting its shares almost 7 percent.

Nov 08 2017

BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln ​

* ‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​

Nov 08 2017

BRIEF-Regeneron and Sanofi to present new analyses from Praluent injection Odyssey clinical trial

* Regeneron and Sanofi to present new analyses from the Praluent® (alirocumab) injection Odyssey clinical trial program at the AHA Scientific Sessions 2017 Source text for Eikon: Further company coverage:

Nov 07 2017

Takeda takes on Sanofi with new global dengue vaccine data

Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

Nov 06 2017

Takeda takes on Sanofi with new global dengue vaccine data

Nov 7 Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

Nov 06 2017

Sanofi takes gloomy view of diabetes drug sales

PARIS French drugmaker Sanofi disappointed investors with a more gloomy forecast for its struggling diabetes business on Thursday, while quarterly net income also slipped.

Nov 02 2017

UPDATE 2-Sanofi takes gloomy view of diabetes drug sales

* CFO sees L'Oreal keeping Sanofi stake for now (Adds details, shares, comments)

Nov 02 2017

Earnings vs. Estimates